Inappropriately regulated expression of
interleukin (IL)-17A is associated with the development of inflammatory diseases and
cancer. However, little is known about the role of other
IL-17 family members in
carcinogenesis. Here, we show that a set of malignant T-cell lines established from patients with
cutaneous T-cell lymphoma (CTCL) spontaneously secrete
IL-17F and that inhibitors of
Janus kinases and
Signal transducer and activator of transcription 3 are able to block that secretion. Other malignant T-cell lines produce
IL-17A but not
IL-17F. Upon activation, however, some of the malignant T-cell lines are able to coexpress
IL-17A and
IL-17F, leading to formation of IL-17A/F heterodimers. Clinically, we demonstrate that
IL-17F messenger RNA expression is significantly increased in CTCL skin lesions compared with healthy donors and patients with chronic
dermatitis.
IL-17A expression is also increased and a significant number of patients express high levels of both
IL-17A and
IL-17F. Concomitantly, we observed that the expression of the
IL-17 receptor is significantly increased in CTCL skin lesions compared with control subjects. Importantly, analysis of a historic cohort of 60 CTCL patients indicates that
IL-17F expression is associated with progressive disease. These findings implicate
IL-17F in the pathogenesis of CTCL and suggest that
IL-17 cytokines and their receptors may serve as therapeutic targets.